Prospects for prevention of childhood infections by maternal immunization

Current Opinion in Infectious Diseases

Volumn 19, Issue 3, 2006, Pages 271-276

  Healy, C Mary ^a   Baker, Carol J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Immune response; Infant infection; Maternal immunization; Passively acquired antibodies; Placental transport

Indexed keywords

ACELLULAR VACCINE; ANTIBIOTIC AGENT; BACTERIAL POLYSACCHARIDE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MATERNAL ANTIBODY; MENINGOCOCCUS VACCINE; NEUTRALIZING ANTIBODY; PALIVIZUMAB; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE; POLYSACCHARIDE; PROTEIN SUBUNIT; RESPIRATORY SYNCYTIAL VIRUS VACCINE; STREPTOCOCCUS VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBODY PRODUCTION; CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVALUATION; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH PROMOTION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFANT DISEASE; INFECTION; INFLUENZA; MATERNAL TREATMENT; NEISSERIA MENINGITIDIS; NEWBORN TETANUS; NONHUMAN; PASSIVE IMMUNIZATION; PATIENT COMPLIANCE; PERTUSSIS; PLACENTAL TRANSFER; PRACTICE GUIDELINE; PREGNANCY; PRIMARY PREVENTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; TETANUS; VACCINATION; VIRUS INFECTION;

DISEASE TRANSMISSION, VERTICAL; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; INFANT; INFANT, NEWBORN; INFECTION; INFECTION CONTROL; MALE; PREGNANCY; VACCINATION;

EID: 33646675803     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000224822.65599.5b     Document Type: Review

References (60)

1. Brent RL. Risks and benefits of immunizing pregnant women: The risk of doing nothing. Reprod Toxicol 2005; doi:10.1016/j.reprotox.2005.09.009 [Epub ahead of print]. Thoughtful review of the current controversies with regard to adopting maternal immunization strategies.
2. Rasmussen SA, Hayes EB. Public health approach to emerging infections among pregnant women. Am J Public Health 2005; 95:1942-1944. This paper gives a brief overview of public health strategies to diagnose and treat infections in pregnant women, and refers briefly to maternal immunization as a preventative strategy.
3. Glezen WP, Alpers M. Maternal immunization. Clin Infect Dis 1999; 28:219-224.
4. Centers for Disease Control and Prevention. Guidelines for vaccinating pregnant women (updated July 2005). Available at http://www.cdc.gov/nip/ publications/preg_guide.htm; accessed February 15, 2006. This presents the latest Guidelines for Vaccinating Pregnant Women from the Centers for Disease Control and Prevention, Atlanta, GA, USA.
5. Farquhar C, Nudati R, Haigwood N, et al. High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody. J Acquir Immune Defic Syndr 2005; 40:494-497.
6. Brair ME, Brabin BJ, Milligan P, et al. Reduced transfer of tetanus antibodies with placental malaria. Lancet 1994; 343:208-209.
7. Ben-Hur H, Gurevich P, Elhayany A, et al. Transport of maternal immunoglobulins through the human placental barrier in normal pregnancy and during inflammation. Int J Mol Med 2005; 16:401-407. This report studies the effect of ascending infection of the birth canal on the transport of maternal immunoglobulins across the placenta, using morphological and immunohistochemical methods.
8. Simister NE. Placental transport of immunoglobulin G. Vaccine 2003; 21:3365-3369.
9. Garty BZ, Ludmirsky A, Danon YL, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994; 1:667-669.
10. Malek A, Sager R, Schneider H. Transport of proteins across the human placenta. Am J Reprod Immunol 1998; 40:347-351.
11. Hasira S, Okitsu-Negishi S, Yoshino K. Placental transfer of IgG subclasses in a Japanese population. Pediatr Int 2000; 42:337-342.
12. Vandalaer J, Birmingham M, Gasse F, et al. Tetanus in developing countries: an update on the Maternal and Neonatal Tetanus Elimination Initiative. Vaccine 2003; 21:3442-3445.
13. World Health Organization. Maternal and neonatal tetanus elimination. Available at http://www.who.int/immunization_monitoring/diseases/ MNTE_initiative/en/; accessed February 14, 2006. This gives an informative and up-to-date account of progress in eliminating puerperal and neonatal tetanus in many countries, and provides projections for the future success of this program.
14. Demicheli V, Barale A, Rivetti A. Vaccines for women to prevent neonatal tetanus. Cochrane Database Syst Rev 2005; 4:CD002959. Cochrane review of the effectiveness of tetanus toxoid administration to women of child-bearing age or pregnant women in preventing neonatal tetanus.
15. Centers for Disease Control and Prevention. Influenza vaccination in pregnancy: practices among obstetrician-gynecologists - United States, 2003-04 influenza season. MMWR Morb Mortal Wkly Rep 2005; 54:1050-1052. This report identifies some of the barriers to successful implementation of the guidelines for influenza vaccination in the US (recommended since 1997) by recording the compliance of obstetricians with the guidelines. This puts the report of excess influenza-related mortality in infants in context.
16. Englund JA. Maternal immunization with inactivated influenza vaccine: rationale and experience. Vaccine 2003; 21:3460-3464.
17. Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000; 342:225-231.
18. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005; 353:2559-2567. This reports US statistics for influenza-related mortality during the 2003-2004 season. It is noteworthy that the highest mortality reported was in infants < 6 months, in whom disease could potentially be prevented if the guidelines for immunization in pregnancy were fully implemented.
19. Reuman PD, Ayoub EM, Small PA. Effect of passive maternal antibody on influenza illness in children: a prospective study of influenza A in mother-infant pairs. Pediatr Infect Dis J 1987; 6:398-403.
20. Schrag SJ, Fiore AE, Gonik B, et al. Vaccination and perinatal infection prevention practices among obstetrician-gynecologists. Obstet Gynecol 2003; 101:704-710.
21. Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2005; 192:1098-1106. This retrospective database study of a large multi-specialty clinic examines the implementation of the CDC guidelines for the vaccination of pregnant women over five influenza seasons, and gives evidence for the safety of maternal immunization by reporting the incidence of adverse effects in mother and infant.
22. Black SB, Shinefield HR, France EK, et al. Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Am J Perinatol 2004; 21:333-339.
23. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-894. This report of antiviral resistance among influenza isolates emphasizes the importance of exploring other methods for preventing or ameliorating influenzarelated morbidity in populations most at risk of severe illness, for example pregnant women and young infants.
24. Mulholland K, Rahaman OS, Siber G, et al. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. JAMA 1996; 275:1182-1188.
25. Englund JA, Glezen WP, Turner C, et al. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. J Infect Dis 1995; 171:99-105.
26. Englund JA, Glezen WP, Thompson C, et al. Haemophilus influenzae type b-specific antibody in infants after maternal immunization. Pediatr Infect Dis J 1997; 16:1122-1130.
27. Shahid NS, Steinhoff MC, Hoque SS, et al. Serum, breast milk, and infant antibody after maternal immunization with pneumococcal vaccine. Lancet 1995; 346:1252-1257.
28. O'Dempsey TJD, McArdle T, Ceesay SJ, et al. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine 1996; 14:963-970.
29. Munoz FM, Englund JA, Cheeseman CC, et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001; 20:826-837.
30. Lockhart NJ, Daly KA, Lindgren BR, et al. Low cord blood type 14 pneumococcal IgG1 but not IgG2 antibody predicts early infant otitis media. J Infect Dis 2000; 181:1979-1982.
31. Richter MY, Jakobsen H, Haeuw JF, et al. Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice. Infect Immun 2005; 73:956-964. This report of infant response to pneumococcal conjugate vaccines in the presence of maternal antibody in an experimental animal model is encouraging, and serves as a backdrop for future studies in humans.
32. Obaro SK, Deubzer HE, Newman VO, et al. Serotype-specific pneumococcal antibodies in breast milk of Gambian women immunized with a pneumococcal polysaccharide vaccine during pregnancy. Pediatr Infect Dis J 2004; 23:1023-1029.
33. Deubzer HE, Obaro SK, Newman VO, et al. Colostrum obtained from women vaccinated with pneumococcal vaccine during pregnancy inhibits epithelial adhesion of Streptococcus pneumoniae. J Infect Dis 2004; 190:1758-1761.
34. Shephard CW, Rosenstein NE, Fischer M, et al. Neonatal meningococcal disease in the United States, 1990 to 1999. Pediatr Infect Dis J 2003; 22:418-422.
35. O'Dempsey TJ, McArdle T, Ceesay SJ, et al. Meningococcal antibody titres in infants of women immunised with meningococcal polysaccharide vaccine during pregnancy. Arch Dis Child Fetal Neonatal Ed 1996; 74:F6-F43.
36. Shahid NS, Steinhoff MC, Roy E, et al. Placental and breast transfer of antibodies after maternal immunization with polysaccharide meningococcal vaccine: a randomized, controlled evaluation. Vaccine 2002; 20:2404-2409.
37. Healy CM, Baker CJ. The future of meningococcal vaccines. Pediatr Infect Dis J 2005; 24:175-176. This paper gives a concise review of the epidemiology of meningococcal disease in the developed and developing world, and summarizes available vaccines and their indications.
38. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19:142-164. Excellent review of advances and limitations of meningococcal vaccine technology, and of how more immunogenic vaccines may reduce meningococcal disease rates.
39. Chanock RM, Parrott RH, Connors M, et al. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics 1992; 90:137-143.
40. Piedra PA. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 2003; 22:S94-S99.
41. Piedra PA. Future directions in vaccine prevention of respiratory syncytial virus. Pediatr Infect Dis J 2002; 21:482-487.
42. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21:3465-3467.
43. Van Rie A, Wendelboe AM, Englund JA. Role of maternal pertussis antibodies in infants. Pediatr Infect Dis J 2005; 24:S62-S65. This is an informative review of the role of maternal antibodies in protecting infants from severe pertussis in the first few months of life. This paper outlines the historical data which support the evaluation of maternal immunization as a preventative strategy, and explores some of the concerns.
44. Tanaka M, Vitek CR, Pascual FB, et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003; 290:2968-2975.
45. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 2003; 22:628-634.
46. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004; 23:985-989.
47. ••], provided the serological and efficacy data which led to the licensure of acellular pertussis vaccines for use in adolescents and adults in the US.
48. ••] , provided the serological and efficacy data which led to the licensure of acellular pertussis vaccines for use in adolescents and adults in the US.
49. Van Savage J, Decker MD, Edwards KM, et al. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990; 161:487-492.
50. Healy CM, Munoz FM, Rench MA, et al. Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004; 190:335-340.
51. Gonik B, Puder KS, Gonik N, Kruger M. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol 2005; 13:59-61. This paper reports levels of maternal pertussis antibodies in a contemporary cohort of mothers and infants.
52. Healy CM, Rench MA, Edwards KM, Baker CJ. Pertussis serostatus among neonates born to Hispanic women. Clin Infect Dis 2006 (in press).
53. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 1995; 96:580-584.
54. Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child 2003; 88:375-378.
55. Schrag SJ, Zell ER, Lynfield R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med 2002; 347:233-239.
56. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003; 21:3468-3472.
57. Lauer P, Rinaudo CD, Soriani M, et al. Genome analysis reveals pili in Group B Streptococcus. Science 2005; 309:105.
58. •], describes how genome technology was used to develop and test a polyvalent GBS vaccine in an animal model. These reports set the stage for further GBS vaccine development.
59. •], describes how genome technology was used to develop and test a polyvalent GBS vaccine in an animal model. These reports set the stage for further GBS vaccine development.
60. Sinha A, Lieu TA, Paoletti LC, et al. The projected health benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis. Vaccine 2005; 23:3187-3195. This paper analyses the likely success of three GBS vaccination strategies (adolescent, maternal or postpartum) used either alone or in combination with chemoprophylaxis in preventing maternal and infant GBS disease.